Lung Cancer Clinical Trials in Las Vegas, NV

View the best 10 lung cancer medical studies in Las Vegas, Nevada. Access promising new therapies by applying to a Las Vegas-based Lung Cancer clinical trial.

Trials in Las Vegas, Nevada

Here are the top 10 medical studies for lung cancer in Las Vegas, Nevada

Michael Bask Gill, B Sc

Last Reviewed: December 6th, 2024

Zimberelimab +2 More

Monoclonal Antibodies

Recruiting1 awardPhase 2

This trial will study the safety and effectiveness of two different immunotherapy treatments for people with non-small cell lung cancer.

9-ING-41

GSK-3β inhibitor

Recruiting1 awardPhase 2

This trial is testing a new drug to see if it is safe and effective in treating cancer. The drug is designed to target a protein called GSK-3β, which is found in many different types of cancer cells.

NovoTTF-200T

Device

Recruiting1 awardPhase 2

This trial is testing a device that sends electric fields to the chest to treat lung cancer along with the drug pembrolizumab. The aim is to see if the combination can help people with lung cancer who haven't been treated before.

FSRS +1 More

Radiation Therapy

Recruiting1 award

This trial evaluates if a lower radiation dose over multiple days reduces side effects vs. one day of full radiation dose for cancer patients on immunotherapy.

FF-10832 +1 More

Anti-metabolites

Recruiting3 awardsPhase 2

This trial is testing a new cancer drug, given in combination with another drug that is already used to treat cancer.

LOXO-292

Tyrosine Kinase Inhibitor

Recruiting1 awardPhase 1 & 2

This trial is testing a new oral drug called selpercatinib in patients with advanced cancers that have specific gene changes. The drug aims to block a gene that helps cancer grow, potentially slowing or stopping the disease.

Docetaxel +1 More

Anti-microtubule agent

Recruiting2 awardsPhase 3

This trial is testing a new drug, sigvotatug vedotin, against a standard drug, docetaxel, in patients with advanced lung cancer. The goal is to see if the new drug works better and to understand its side effects. Docetaxel (Taxotere) is a well-established chemotherapy agent used in the treatment of advanced non-small cell lung cancer (NSCLC), often after failure of first-line treatments.

Osimertinib

Tyrosine Kinase Inhibitor

Recruiting2 awardsPhase 3

This trial is testing whether adding chemotherapy to osimertinib will help people with non-small cell lung cancer that has a specific DNA mutation and has gotten worse despite osimertinib.

XL092

Recruiting1 awardPhase 1

This trial is testing a new drug called XL092 alone and with other cancer drugs in patients with advanced solid tumors. The goal is to see if these treatments can safely stop or slow tumor growth and help the immune system fight cancer more effectively.

Atezolizumab

Checkpoint Inhibitor

Recruiting2 awardsPhase 3

This trial is testing a new cancer treatment against the current best treatment, to see if the new treatment is more effective in preventing the cancer from returning.

Popular Filters

Phase 3 Trials

Chemotherapy

Immunotherapy + Chemotherapy for Lung Cancer

Recruiting2 awardsPhase 3

Las Vegas, Nevada

This trial is testing a new way to treat lung cancer that may be more effective and have fewer side effects than the current standard of care.

Checkpoint Inhibitor

Nivolumab +/- Ipilimumab for Lung Cancer

Recruiting2 awardsPhase 3

Rancho Mirage, California

This trial is testing nivolumab with or without ipilimumab to see if it can treat patients with squamous cell lung cancer that has come back after previous treatment.

Checkpoint Inhibitor

Atezolizumab After Chemotherapy for Lung Cancer

Recruiting2 awardsPhase 3

Henderson, Nevada

This trial is testing a new cancer treatment against the current best treatment, to see if the new treatment is more effective in preventing the cancer from returning.

Topoisomerase I inhibitors

Chemotherapy +/− Ganitumab for Ewing Sarcoma

Recruiting2 awardsPhase 3

Loma Linda, California

This trial is testing how well combination chemotherapy works with or without the drug ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Tyrosine Kinase Inhibitor

Crizotinib for Non-Small Cell Lung Cancer

Recruiting2 awardsPhase 3

Kingman, Arizona

This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.

Tyrosine Kinase Inhibitor

Alectinib vs Crizotinib for Non-Small Cell Lung Cancer

Recruiting2 awardsPhase 3

Las Vegas, Nevada

This trial compares two medications, alectinib and crizotinib, for treating a specific type of advanced lung cancer. The patients have not received any prior treatment for their cancer. Both drugs work by blocking a protein that helps the cancer cells grow. Alectinib has shown superior effectiveness and fewer side effects compared to crizotinib in treating this type of lung cancer.

Trials With No Placebo

Tyrosine Kinase Inhibitor

Selpercatinib for Solid Tumors

Recruiting1 awardPhase 1 & 2

Las Vegas, Nevada

This trial is testing a new oral drug called selpercatinib in patients with advanced cancers that have specific gene changes. The drug aims to block a gene that helps cancer grow, potentially slowing or stopping the disease.

Chemotherapy

Immunotherapy + Chemotherapy for Lung Cancer

Recruiting2 awardsPhase 3

Las Vegas, Nevada

This trial is testing a new way to treat lung cancer that may be more effective and have fewer side effects than the current standard of care.

Checkpoint Inhibitor

Nivolumab +/- Ipilimumab for Lung Cancer

Recruiting2 awardsPhase 3

Rancho Mirage, California

This trial is testing nivolumab with or without ipilimumab to see if it can treat patients with squamous cell lung cancer that has come back after previous treatment.

Checkpoint Inhibitor

Atezolizumab After Chemotherapy for Lung Cancer

Recruiting2 awardsPhase 3

Henderson, Nevada

This trial is testing a new cancer treatment against the current best treatment, to see if the new treatment is more effective in preventing the cancer from returning.

Kinase Inhibitor

Targeted Therapy for Cancer

Recruiting1 awardPhase 2

Kingman, Arizona

This trial uses genomic testing to direct cancer treatment. Patients with cancer that has progressed after standard treatment or for which there is no agreed-upon treatment may benefit.

Topoisomerase I inhibitors

Chemotherapy +/− Ganitumab for Ewing Sarcoma

Recruiting2 awardsPhase 3

Loma Linda, California

This trial is testing how well combination chemotherapy works with or without the drug ganitumab in treating patients with newly diagnosed Ewing sarcoma.

View more lung-cancer clinical trials las-vegas

See more medical studies focusing on lung-cancer las-vegas

Frequently Asked Questions

Do I need insurance to participate in a trial?

Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).

Is there any support for travel costs?

Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.

Will I know what medication I am taking?

This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.

How long do clinical trials last?

Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.

Do you verify all the trials on your website?

All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.

How quickly will I hear back from a clinical trial?

Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.